Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: attention (180), absorption (28), meditation (10), awareness (151), focus (321), strength (181)

Erdafitinib

Description: Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or metasta
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Ad
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

ACCORD-2 master protocol

Description: CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisat
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf

Capecitabine-Epirubicin-Oxaliplatin (EOX)

Description: Chemotherapy Protocol GASTROINTESTINAL (UPPER) CANCER CAPECITABINE, EPIRUBICIN and OXALIPLATIN (EOX) Regimen • Gastrointestinal
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Upper-gastro-intestinal/Capecitabine-Epirubicin-Oxaliplatin.pdf

DA_3+8

Description: Regimen Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA DA (3+8)–Cytarabine-Daunorubicin In-Patient Regimen • Acute Myeloid Leukaemia – InP-DA (3+8)–Cytarabine-Daunorubicin Indication • Consolidatio
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8.pdf

DA_3+10

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA DA (3+10)–Cytarabine-Daunorubicin In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-DA (3+10)–Cytarabine-Daunorubicin Indication • Acute myel
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-10.pdf

DA_3+8_CADD

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA Ambulatory Regimen AmB - DA (3+8) CADD–Cytarabine-Daunorubicin Regimen • Acute Myeloid Leuk
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-3-8-CADD.pdf

AmB-(TICE)-Carboplatin-Etoposide

Description: Chemotherapy Protocol GERM CELL Amb TICE (Part 2): Carboplatin – Etoposide phosphate Ambulatory Regimen This regimen is for AMBULATORY CARE pathway u
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/AmB-TICE-Carboplatin-Etoposide.pdf

DA_2+5

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA DA (2 + 5) – Cytarabine-Daunorubicin In-Patient Regimen Regimen • Acute Myeloid Leukaemia – InP-DA (2+5)–Cytarabine-Daunorubicin Indication • Consolid
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/DA-2-5.pdf

Gefitinib

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) GEFITINIB Regimen NSCLC - Gefitinib Indication Gefitinib is recommended as an option for the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Gefitinibver13.pdf

1 to 10 of 83

Previous 1 2 3 4 5 … Next